Updated just now · Live
Stock analysis, price data, and AI-powered insights for AnaptysBio Inc (ANAB).
AnaptysBio Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for ANAB.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). ANAB Stock Intelligence Report. [stoxpulse.com/stocks/anab]
Disclaimer: The information on this page about AnaptysBio Inc (ANAB) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for AnaptysBio Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To ...
4h ago
Top movers analysis one hour before the close of t...
1d ago
StoxPulse AI results for ANAB: Pulse Score 60/100. Primary sentiment trends from 10 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$1.46B
P/E Ratio
—
EPS
$0.52
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics
Top movers analysis one hour before the close of the markets on 2026-04-20: top gainers and losers in today's session.
What's going on in today's session
These stocks are gapping in today's session
12 Health Care Stocks Moving In Monday's Intraday Session
Top movers in Monday's pre-market session
AnaptysBio shares are trading lower after the company announced it completed the spin-off of First Tracks Biotherapeutics
AnaptysBio Completes Spin-Off Of First Tracks Biotherapeutics; Anaptys To Now Exclusively Manage Financial Collaborations For Jemperli With GSK And Imsidolimab With Vanda